January 10, 2018 Source: Emergo 161
The China Food and Drug Administration (CFDA) has announced new and updated regulations for medical device registration, testing and clinical trial requirements in the early days of 2018.
The regulator’s latest batch of updates includes medical device clinical trial design, in-country device testing and mobile medical devices, according to Emergo consultants in Hong Kong.
First, CFDA has issued new technical guidance (link in Chinese) for clinical trial designs. The new guidance includes information regarding selection of study endpoints, methods for calculating sample sizes and related study design considerations.
Second, new technical guidance (link in Chinese) has been issued to clarify what CFDA considers mobile medical devices. According to CFDA, “mobile medical device” refers to software and equipment that utilize non-invasive mobile computing terminals such as handheld smartphones and tablets, wearables as well as commercial off-the-shelf technologies to perform medical functions.
Next, a new CFDA notice (link in Chinese) was published in late 2017 for the agency’s local-level offices and device testing centers; the notice advises the following:
This clarification follows a shift in CFDA policy in 2017 in which medical device registrants were no longer assessed testing fees; issues including delayed testing timeframes and some local test centers no longer accepting applications from foreign registrants have arisen since this policy shift, so the new notice may help address these discrepancies.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.